BCTX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-121.6K ExitQ4 2025 $122k -- --
Ken GriffinCitadel Advisors $-121.6K ExitQ4 2025 $122k -- --

News

globenewswire.comBriaCell Therapeutics Announces Closing of Offeringglobenewswire.comJun 2

globenewswire.comBriaCell Presents Positive Clinical Data at ASCO 2026globenewswire.comJun 1

globenewswire.comBriaCell Therapeutics Announces Pricing of Offeringglobenewswire.comMay 31

globenewswire.comBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancerglobenewswire.comMay 26

globenewswire.comBriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026globenewswire.comMay 22

Trade BCTX

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

CEO: William V. Williams
IPO Date: Mar 14, 2012

Market Data

Open: $2.85
High: $2.94
Low: $2.80
Volume: 54.6K
Avg Volume: 208.2K
52W High: $31.60
52W Low: $2.60

Valuation

Market Cap: $5.5M
Enterprise Value: $-1.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-39M
Revenue: $0
Net Income: $-36M
Cash: $14M
Debt: $0

Events

EarningsJun 9

actual -0.99